GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » RUA Life Sciences PLC (FRA:AOHA) » Definitions » Net Income

RUA Life Sciences (FRA:AOHA) Net Income : €-2.15 Mil (TTM As of Sep. 2023)


View and export this data going back to . Start your Free Trial

What is RUA Life Sciences Net Income?

Net Income is the net profit that a company earns after deducting all costs and losses including cost of goods, SGA, DDA, interest expenses, non-recurring items and tax. RUA Life Sciences's Net Income for the six months ended in Sep. 2023 was €-1.17 Mil. Its Net Income for the trailing twelve months (TTM) ended in Sep. 2023 was €-2.15 Mil.

Net Income is linked to the most popular Earnings per Share (Diluted) number. RUA Life Sciences's Earnings per Share (Diluted) for the six months ended in Sep. 2023 was €-0.05.


RUA Life Sciences Net Income Historical Data

The historical data trend for RUA Life Sciences's Net Income can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

RUA Life Sciences Net Income Chart

RUA Life Sciences Annual Data
Trend Mar14 Mar15 Mar16 Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23
Net Income
Get a 7-Day Free Trial Premium Member Only Premium Member Only -0.71 -0.91 -1.69 -2.47 -2.27

RUA Life Sciences Semi-Annual Data
Mar14 Sep14 Mar15 Sep15 Mar16 Sep16 Mar17 Sep17 Mar18 Sep18 Mar19 Sep19 Mar20 Sep20 Mar21 Sep21 Mar22 Sep22 Mar23 Sep23
Net Income Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -1.53 -0.90 -1.31 -0.98 -1.17

RUA Life Sciences Net Income Calculation

Net Income is the net profit that a company earns after deducting all costs and losses including cost of goods, SGA, DDA, interest expenses, non-recurring items and tax.

Net Income
= Revenue - Cost of Goods Sold - Selling, General, & Admin. Expense - Research & Development - Depreciation, Depletion and Amortization - Interest Expense - Non Operating Income (NRI) - Tax Expense + Others
= EBITDA - Depreciation, Depletion and Amortization - Interest Expense - Non Operating Income (NRI) - Tax Expense + Others
= Operating Income - Interest Expense - Non Operating Income (NRI) - Tax Expense + Others
= Pre-Tax Income - Tax Expense + Others

RUA Life Sciences's Net Income for the fiscal year that ended in Mar. 2023 is calculated as

Net Income(A: Mar. 2023 )
= Pre-Tax Income + Tax Provision + Net Income (Discontinued Operations) + Others
=-2.632+0.362+0+0
=-2.27

RUA Life Sciences's Net Income for the quarter that ended in Sep. 2023 is calculated as

Net Income(Q: Sep. 2023 )
= Pre-Tax Income + Tax Provision + Net Income (Discontinued Operations) + Others
=-1.619+0.448+0+0
=-1.17

Net Income for the trailing twelve months (TTM) ended in Sep. 2023 adds up the semi-annually data reported by the company within the most recent 12 months, which was €-2.15 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


RUA Life Sciences  (FRA:AOHA) Net Income Explanation

Net Income is the most widely cited number in reporting a company's profitability. It is linked to the most popular earnings-per-share (EPS) number through:

RUA Life Sciences's Earnings per Share (Diluted) (EPS) for the quarter that ended in Sep. 2023 is calculated as

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Although Net Income and Earnings-per-Share (EPS) are the most widely used parameter in measuring a company's profitability and valuation, it is the least reliable. The reason is that reported earnings can be manipulated easily by adjusting any numbers such as Depreciation, Depletion and Amotorization and non-recurring items.

EPS is most useful for companies that have:

A predictable business
Consistent accounting methods
And few restructurings

The dividend paid to preferred stocks needs to be subtracted from the total net income in the calculation of EPS because common stock holders are not entitled to that part of the net income.


Be Aware

Warren Buffett looks for consistency and upward long term trend. Because of share repurchase it is possible for net earnings trend to differ from EPS trend. He preferred Net Income over EPS. The companies with durable competitive advantage companies report higher % net earnings to total revenues.

Important: If a company is showing net earnings history greater than 20% on total revenues, it is probably benefiting from a long term competitive advantage.

If net earnings is less than 10%, likely to be in a highly competitive business.


RUA Life Sciences Net Income Related Terms

Thank you for viewing the detailed overview of RUA Life Sciences's Net Income provided by GuruFocus.com. Please click on the following links to see related term pages.


RUA Life Sciences (FRA:AOHA) Business Description

Traded in Other Exchanges
Address
2 Drummond Crescent, Scotland, Irvine, Ayrshire, GBR, KA11 5AN
RUA Life Sciences PLC is a biomedical polymer technology, components, and medical device company. The company's principal activities comprise exploiting the value of its IP and know-how, medical device contract manufacturing, and development of cardiovascular devices. Its business segments are Royalty and License Income (Biomaterials), Contract Manufacture, Product Development (Vascular), and Product Innovation (Structural Heart). It derives the majority of its revenue from the Contract Manufacture segment. Geographically, it derives its major revenue from the USA and has a presence in Europe and the Rest of the world.

RUA Life Sciences (FRA:AOHA) Headlines

No Headlines